Pancreatic Cancer Treatment in Nepal Symptoms, Diagnosis & Care at KCC
Kathmandu Cancer Center offers Whipple surgery, FOLFIRINOX chemotherapy, and PARP inhibitor therapy for pancreatic cancer — expert multidisciplinary care in Nepal, without the cost and stress of travelling to India.
What Is Pancreatic Cancer?
Pancreatic cancer (अग्न्याशय क्यान्सर) is a malignant tumour arising from cells of the pancreas — a gland that sits behind the stomach and produces digestive enzymes and hormones including insulin. The most common type, pancreatic ductal adenocarcinoma (PDAC), makes up approximately 90% of cases and originates in the cells lining the pancreatic ducts. Because the pancreas lies deep within the abdomen and early tumours cause few symptoms, most patients are diagnosed at an advanced stage. It is one of the most challenging cancers to treat, but surgery offers a genuine chance of cure when the disease is detected early enough. Modern chemotherapy regimens such as FOLFIRINOX have significantly improved outcomes even for advanced disease.
Anatomy: Head, Body, and Tail
The pancreas has three regions. About 70% of pancreatic cancers arise in the head — near the bile duct — where they cause obstructive jaundice, often the earliest detectable sign. Cancers of the body and tail produce no biliary obstruction and typically present later with back pain and weight loss.
Ductal adenocarcinoma, acinar cell carcinoma — ~95% of all pancreatic cancers
Insulinoma, gastrinoma, non-functioning PNETs — generally better prognosis
IPMN, mucinous cystic neoplasm — some are premalignant and warrant surveillance
Pancreatic Cancer Symptoms
Pancreatic cancer is often called a "silent disease" because early tumours rarely produce noticeable symptoms. By the time most patients in Nepal present to a doctor, the disease has reached an advanced stage. Knowing these warning signs — in Nepali and English — can save lives.
Early Warning Signs — Act Promptly
- Painless jaundice — yellowing of skin and eyes (आँखा र छाला पहेँलो हुनु) Most common first sign; caused by bile duct blockage by a head-of-pancreas tumour
- New-onset diabetes after age 50 — sudden unexplained blood sugar problems Pancreatic cancer can destroy insulin-producing cells; new diabetes in an older adult warrants evaluation
- Dark urine (गाढा पिसाब) and pale or greasy stools (हल्का वा चिल्लो दिसा)
- Unexplained weight loss (अकारण तौल घट्नु) and loss of appetite (भोक नलाग्नु)
Common Symptoms of Advanced Disease
- Upper abdominal or back pain (पेट वा ढाडमा दुखाइ) — dull, persistent ache, often worse lying flat
- Nausea and vomiting (वाकवाकी र बान्ता)
- Bloating and indigestion
- Blood clots (DVT/PE) — pancreatic cancer is strongly pro-thrombotic; unexplained clots in young patients should prompt evaluation
- Ascites — fluid in the abdomen (पेटमा पानी जम्नु)
- Fatigue and weakness (थकान र कमजोरी)
Risk Factors for Pancreatic Cancer
2–3× higher risk; the most important modifiable risk factor
Long-standing pancreatic inflammation significantly raises risk
Long-standing diabetes is both a risk factor and an early symptom
Abdominal obesity increases risk independently
First-degree relative with pancreatic cancer; BRCA1/2 and PALB2 mutations
Via chronic pancreatitis; direct risk modest
Pancreatic Cancer Diagnosis at KCC
Accurate staging is the most important step in pancreatic cancer management — it determines whether a patient can undergo curative surgery. KCC uses a structured multidisciplinary approach reviewed by our full oncology team.
Clinical Assessment & Blood Tests
Full history, physical examination, liver function tests (LFTs), and tumour markers.
- CA 19-9 — the primary pancreatic tumour marker; used for diagnosis and monitoring
- CEA — supplementary marker
- Liver function panel & bilirubin — for obstructive jaundice assessment
Important: CA 19-9 is not specific and a normal result does not exclude cancer. 10% of people lack the Lewis antigen and cannot produce CA 19-9 even with active disease. Always interpret alongside imaging.
Staging CT Scan (Pancreatic Protocol)
A triple-phase contrast CT of the abdomen and pelvis is the cornerstone of pancreatic cancer staging. It defines:
- Tumour size and location (head, body, or tail)
- Relationship to key vessels (SMA, SMV, portal vein, coeliac axis) — determines resectability
- Liver metastases, peritoneal disease, lymph node spread
MRI/MRCP is added when liver lesions are equivocal, or for biliary anatomy and cystic lesion characterisation. Chest CT excludes pulmonary metastases.
Tissue Biopsy — Histological Confirmation
For resectable tumours, biopsy is often deferred to the time of surgery. For unresectable or metastatic disease, biopsy is obtained via:
- EUS-guided fine needle aspiration (EUS-FNA) — gold standard for pancreatic masses; avoids peritoneal seeding
- CT-guided biopsy — for accessible lesions or liver metastases
- ERCP with brush cytology — when biliary stenting for jaundice relief is needed simultaneously
Molecular & Genetic Testing
KCC recommends molecular profiling for eligible patients:
- Germline BRCA1/BRCA2 testing — identifies patients eligible for olaparib maintenance therapy
- KRAS, NTRK, HER2 somatic profiling — for emerging targeted therapies
- MSI-H / dMMR — identifies rare patients eligible for pembrolizumab immunotherapy
Multidisciplinary Tumour Board Review
Every pancreatic cancer case at KCC is discussed at our Multidisciplinary Tumour Board (MDT) — surgical oncology, medical oncology, radiation oncology, radiology, and pathology together — before a treatment plan is finalised. This is standard of care and is not routinely available outside dedicated cancer centres in Nepal.
Resectability: The Critical Staging Question
| Category | What It Means | Standard Approach |
|---|---|---|
| Resectable | Tumour clear of major vessels; surgery possible upfront | Surgery → 6 months adjuvant chemotherapy |
| Borderline Resectable | Tumour abuts vessels; may become resectable after chemotherapy | Neoadjuvant FOLFIRINOX × 4–6 cycles → restage → surgery |
| Locally Advanced | Tumour encases vessels; surgery not currently feasible | Chemotherapy ± SBRT; reassess for conversion to surgery |
| Metastatic | Spread to liver, lungs, peritoneum, or distant nodes | FOLFIRINOX or Gem + nab-P; best supportive care |
Pancreatic Cancer Treatment Options at KCC
Treatment is guided by tumour stage, location, and the patient's overall fitness. KCC offers the complete range of curative and palliative options — all in Nepal.
Surgery — The Only Curative Option
Surgical resection is the only treatment that offers a chance of cure for pancreatic cancer. KCC's surgical oncology team performs all three major pancreatic resections:
Whipple Procedure (Pancreaticoduodenectomy)
The standard curative surgery for head of pancreas cancers. Removes the pancreatic head, duodenum, gallbladder, part of the bile duct, and sometimes part of the stomach, then reconstructs the digestive tract. This 5–8 hour operation requires highly specialised surgical expertise and intensive post-operative care — both available at KCC.
Indicated for: Pancreatic head / periampullary / bile duct tumoursDistal Pancreatectomy
Removes the body and tail of the pancreas, typically with the spleen. Spleen-preserving variants exist for benign or borderline lesions. Performed for cancers of the body and tail.
Indicated for: Body/tail pancreatic tumours, PNETs, mucinous cystic neoplasmsTotal Pancreatectomy
Removes the entire pancreas, duodenum, spleen, and gallbladder. Reserved for diffuse disease or when positive surgical margins are anticipated. Patients require lifelong insulin therapy and pancreatic enzyme replacement.
Indicated for: Multifocal tumours, diffuse high-grade IPMN, margin-positive completionChemotherapy
Chemotherapy is the backbone of systemic treatment for pancreatic cancer, used in the neoadjuvant, adjuvant, and metastatic settings. KCC offers all major regimens recommended by NCCN and ESMO guidelines:
Combination of oxaliplatin, irinotecan, leucovorin and 5-fluorouracil. The most active regimen for metastatic pancreatic cancer in patients with ECOG performance status 0–1. Also used as neoadjuvant therapy to downstage borderline resectable disease before surgery. Available at KCC.
Effective and generally better tolerated than FOLFIRINOX; suitable for patients with slightly reduced performance status. Also used in the neoadjuvant and adjuvant settings.
Six months of adjuvant chemotherapy (modified FOLFIRINOX or gemcitabine monotherapy) significantly reduces relapse risk after curative pancreatic resection. KCC's medical oncology team manages this post-operative phase.
Targeted Therapy & Precision Oncology
Erlotinib (EGFR Inhibitor)
Combined with gemcitabine for metastatic pancreatic cancer. Provides a modest survival benefit in an unselected population. Available at KCC as part of the first-line treatment arsenal.
Olaparib (PARP Inhibitor) — For BRCA-Positive Patients
Patients with a germline BRCA1 or BRCA2 mutation who have not progressed on first-line platinum-based chemotherapy (typically FOLFIRINOX) are eligible for olaparib (Lynparza) maintenance therapy. Approximately 5–7% of pancreatic cancer patients carry a BRCA mutation. KCC offers both the germline genetic testing and the olaparib treatment, making this precision approach available in Nepal for the first time.
Radiation Oncology
Radiotherapy has defined roles in pancreatic cancer — particularly for locally advanced disease and selected borderline resectable cases.
- SBRT (Stereotactic Body Radiotherapy) — ablative, high-precision doses in 3–5 fractions. Used for locally advanced unresectable pancreatic cancer to achieve local control and occasionally enable surgical conversion.
- Chemoradiation — concurrent gemcitabine or capecitabine with radiation for locally advanced disease, following initial chemotherapy induction.
- Palliative radiation — for pain from bone or neural involvement, or symptomatic local disease.
Supportive & Palliative Care
Pancreatic cancer causes significant symptom burden. KCC's integrated supportive care programme addresses:
- Biliary stenting / ERCP — to relieve obstructive jaundice and restore liver function before surgery or systemic therapy
- Pancreatic enzyme replacement therapy (PERT) — to manage exocrine insufficiency, malabsorption, and weight loss
- Pain management — including coeliac plexus block / neurolysis for refractory upper abdominal pain
- Nutritional support — oncology dietitian input; enteral or parenteral nutrition where needed
- Post-pancreatectomy diabetes care — insulin management and glucose monitoring after surgery
- Palliative care integration — symptom control and quality-of-life support from the time of diagnosis
Pancreatic Cancer Treatment Cost in Nepal
Treating pancreatic cancer at KCC costs a fraction of equivalent care at major Indian or Thai cancer centres — and without the burden of travel, accommodation, visas, and family separation. Below are indicative ranges for planning purposes:
| Treatment | Approx. Cost at KCC (NPR) | Notes |
|---|---|---|
| Diagnostic workup (CT + CA 19-9 + biopsy) | 25,000 – 60,000 | Varies by tests ordered |
| Whipple surgery (Pancreaticoduodenectomy) | 4,00,000 – 7,00,000 | Incl. 10–14 day hospitalisation |
| Distal / Total Pancreatectomy | 3,00,000 – 5,50,000 | Incl. hospitalisation |
| FOLFIRINOX (per cycle) | 30,000 – 55,000 | Typically 6–12 cycles |
| Gemcitabine + nab-Paclitaxel (per cycle) | 40,000 – 70,000 | nab-Paclitaxel cost varies |
| SBRT / IMRT radiotherapy course | 80,000 – 1,50,000 | Depending on technique and fractions |
| Olaparib (Lynparza) — per month | On application | Access programmes may be available; discuss with team |
All figures are indicative and subject to change. Final costs depend on the individual treatment plan. Nepal government health insurance (NHIS / SSF / social health schemes) may cover partial costs. KCC's financial counsellors can assist with insurance claims and cost planning.
Full Treatment Cost Guide →Frequently Asked Questions
Can pancreatic cancer be treated in Nepal?
Yes. Kathmandu Cancer Center offers the full spectrum of pancreatic cancer treatment — Whipple surgery (pancreaticoduodenectomy), distal and total pancreatectomy, FOLFIRINOX, Gemcitabine + nab-paclitaxel, erlotinib, and olaparib (PARP inhibitor) for BRCA-positive patients. Patients no longer need to travel to India or Bangkok for pancreatic cancer care.
What are the earliest signs of pancreatic cancer? (अग्न्याशय क्यान्सरका प्रारम्भिक लक्षणहरू के हुन्?)
Pancreatic cancer is often silent in early stages. The most recognisable early sign is painless jaundice — yellowing of the skin and eyes (आँखा र छाला पहेँलो हुनु). Other warning signs include unexplained weight loss, new-onset diabetes after age 50, pale or greasy stools, dark urine, and mild upper abdominal or back discomfort. Anyone with these symptoms should seek urgent medical evaluation — earlier diagnosis significantly improves treatment options.
What is the Whipple operation (Whipple Surgery) and is it available in Nepal?
The Whipple procedure (pancreaticoduodenectomy) is the standard curative surgery for cancers of the head of the pancreas. It involves removing the pancreatic head, duodenum, gallbladder, and part of the bile duct, followed by reconstruction of the digestive tract. This complex 5–8 hour operation is performed at Kathmandu Cancer Center, Nepal, by our specialist surgical oncology team. There is no longer a need to travel to India or abroad for this procedure.
What does "borderline resectable" pancreatic cancer mean?
Borderline resectable means the tumour is close to — but not clearly encasing — major blood vessels like the superior mesenteric artery or portal vein. Surgery may still be possible, but only after neoadjuvant (pre-surgery) chemotherapy with FOLFIRINOX to shrink the tumour and create a safe surgical margin. KCC's multidisciplinary tumour board reviews all borderline resectable cases to plan the optimal treatment sequence.
Is FOLFIRINOX chemotherapy available in Nepal?
Yes. FOLFIRINOX — a combination of oxaliplatin, irinotecan, leucovorin, and 5-fluorouracil — is available at Kathmandu Cancer Center. It is the most effective chemotherapy regimen for fit patients with metastatic pancreatic cancer and is also used as neoadjuvant therapy to downstage borderline resectable tumours before surgery.
What is olaparib and who with pancreatic cancer is eligible for it?
Olaparib (Lynparza) is a PARP inhibitor — an oral targeted therapy. It is used as maintenance treatment for patients with metastatic pancreatic cancer who carry a germline BRCA1 or BRCA2 mutation and whose disease has not progressed on first-line platinum-based chemotherapy (typically FOLFIRINOX). Approximately 5–7% of pancreatic cancer patients are BRCA-positive. KCC offers germline BRCA testing and olaparib therapy — contact our team to discuss eligibility.
Does pancreatic cancer run in families? Should I get genetic testing?
Approximately 10% of pancreatic cancers are linked to inherited mutations in BRCA1, BRCA2, PALB2, ATM, or Lynch syndrome genes. If you have a first-degree relative with pancreatic cancer, or a family history of breast, ovarian, or colorectal cancer, genetic counselling and testing is strongly recommended. KCC's Molecular Tumour Board (led by Dr. Simit Sapkota) offers germline testing and interprets results to guide treatment decisions.
How much does pancreatic cancer treatment cost in Nepal compared to India?
Treatment at KCC costs significantly less than comparable care at major Indian oncology centres. A Whipple surgery at KCC costs approximately NPR 4–7 lakhs, compared to INR 6–12 lakhs (roughly NPR 9–18 lakhs equivalent) at Indian centres — and that is before adding the cost of travel, accommodation, and time away from home. See our full cost guide for detailed estimates across all treatment modalities.
अग्न्याशय क्यान्सर — नेपालीमा जानकारी
अग्न्याशय क्यान्सर भनेको के हो?
अग्न्याशय (Pancreas) पेटको पछाडि रहने एउटा ग्रन्थी हो जसले पाचन एन्जाइम र इन्सुलिन उत्पादन गर्छ। अग्न्याशय क्यान्सर यसै ग्रन्थीमा उत्पन्न हुने घातक ट्युमर हो। यो रोग प्रायः ढिलो पत्ता लाग्छ किनभने सुरुवाती अवस्थामा सामान्यतया लक्षणहरू देखिँदैनन्।
मुख्य लक्षणहरू
- 🟡 आँखा र छाला पहेँलो हुनु (Jaundice) — सबैभन्दा महत्वपूर्ण प्रारम्भिक संकेत
- ⚖️ अकारण तौल घट्नु (Unexplained weight loss)
- 😞 भोक नलाग्नु (Loss of appetite)
- 🔴 पेट वा ढाडमा दुखाइ (Abdominal or back pain)
- 🟫 गाढा पिसाब र हल्का दिसा (Dark urine, pale stools)
- 🩸 अचानक मधुमेह देखिनु (New-onset diabetes — especially after age 50)
काठमाडौं क्यान्सर केन्द्र (KCC) मा उपलब्ध उपचार
- ✅ Whipple अपरेसन (Pancreaticoduodenectomy) — अग्न्याशयको टाउकोमा भएको क्यान्सरको मुख्य शल्यक्रिया, अब नेपालमै
- ✅ Distal Pancreatectomy — अग्न्याशयको शरीर र पुच्छर भागको शल्यक्रिया
- ✅ Total Pancreatectomy — सम्पूर्ण अग्न्याशय हटाउने शल्यक्रिया
- ✅ FOLFIRINOX किमोथेरापी — उन्नत क्यान्सरको लागि सबैभन्दा प्रभावकारी उपचार
- ✅ Gemcitabine + nab-Paclitaxel — वैकल्पिक किमोथेरापी, राम्रो सहनशीलता
- ✅ PARP Inhibitor (Olaparib / Lynparza) — BRCA जीन भएका बिरामीका लागि लक्षित उपचार
- ✅ रेडियोथेरापी विकिरण उपचार — स्थानीय रूपमा उन्नत क्यान्सरको लागि उच्च-परिशुद्धता रेडियोथेरापी
भारत वा विदेश जान नपरोस्। अग्न्याशय क्यान्सरको सम्पूर्ण उपचार — Whipple अपरेसनदेखि उन्नत किमोथेरापी र लक्षित उपचारसम्म — अब KCC मा नेपालमै उपलब्ध छ। परामर्शका लागि आजै सम्पर्क गर्नुहोस्।
अपोइन्टमेन्ट बुक गर्नुहोस्